Pharmaceutical giants wager on AI to expedite clinical trials

 

Major pharmaceutical companies are employing artificial intelligence to speed up the process of finding participants for clinical trials and potentially save millions of dollars by reducing the number of individuals required to test drugs.

Businesses like Amgen, Bayer, and Novartis are teaching AI to search through billions of public health records, prescription data, medical insurance claims, and internal data to discover trial patients, sometimes cutting the time it takes to sign them up in half.

 

The U.S. Food and medication Administration (FDA) reported that from 2016 to 2022, it had received around 300 applications involving the use of AI or machine learning in medication development. More than 90% of those applications were submitted in the last two years, and the majority involved using AI at some stage of clinical development.

Source: https://www.reuters.com/technology/big-pharma-bets-ai-speed-up-clinical-trials-2023-09-22/ 

 

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)